ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics (NYSE:ADCT) reported Q3 adjusted losses of $(0.41) per share, beating the analyst consensus estimate of $(0.63) by 34.92%. However, the company's quarterly sales of $14.49 million missed the analyst consensus estimate of $15.99 million by 9.36%. This represents a 415.38% decrease in earnings and an 81.01% decrease in sales compared to the same period last year.
November 07, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ADC Therapeutics reported better-than-expected Q3 losses but missed on sales. The company's earnings and sales have significantly decreased compared to the same period last year.
ADC Therapeutics reported a smaller loss than expected, which is positive. However, the company missed sales estimates and reported a significant year-over-year decrease in both earnings and sales. This could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100